Pemphigus Vulgaris – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the diagnosed incidence and prevalence of PV for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s PV forecast will answer the following questions:

  • How many people in each country across the major mature pharmaceutical markets have been formally diagnosed with PV?
  • How does the severity of HS differ between newly diagnosed and existing prevalent PV cases?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PV over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts five HS patient populations, as follows:

  • Diagnosed incident cases.
  • Diagnosed prevalent cases.
  • Diagnosed incident cases by severity.

Note: coverage may vary by country.

launch Related Market Assessment Reports